While deficiencies of either Fas or FasL resulted in an increase in tumor burden, in the current study, the increases in tumor number ranged from ∼300%, at early time points, to over 500%, at 16 weeks, whereas Fingleton et al. observed an increase nearly 100% at 17 weeks. This evidence concerns the gene FAS and neoplasm.